News & Events
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
Piha-Paul SA1, Taylor MH2, Spitz D3, Schwartzberg L4, Beck JT5, Bauer TM6, Meric-Bernstam F1, Purkayastha D7, Karpiak L7, Szpakowski S8, Braiteh F9 https://www.ncbi.nlm.nih.gov/pubmed/31741715
Quality Cancer Care Alliance Network (QCCA) Selects Integra Connect as Preferred Population Health Analytics Partner
November 19, 2019QCCA Network of 20 Oncology Practices to Integrate Population Health Analytics Solutions to Achieve Clinical and Financial Objectives Under Value-Based Care The… Quality Cancer Care Alliance Network (QCCA) Selects Integra Connect as Preferred Population Health Analytics Partner
Pietrantonio F1,2, Di Nicolantonio F3,4, Schrock AB5, Lee J6, Morano F1, Fuca G1, Nikolinakos P7, Drilon A8, Hechtman JF9, Christiansen J10, Gowen K5, Frampton GM5,… RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.
Nassar AH1, Hamieh L2, Gray KP3, Thorner AR4, Fay AP5, Lasseter KD1, Abou Alaiwi S2, Nuzzo PV2, Flippot R2, Krajewski KM6, Signoretti S7, Choueiri TK2, Kwiatkowski DJ8. https://www.ncbi.nlm.nih.gov/pubmed/31653662
Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database.
Shah CP1, Mramba LK2, Bishnoi R1, Unnikrishnan A3, Duff JM1,4, Chandana SR5,6,7. https://www.ncbi.nlm.nih.gov/pubmed/31602324
Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells.
Zhao W, Liu Y, Jenkins BD, Cheng R, Harris BN, Zhang W, Xie J, Murrow JR, Hodgson J, Egan M, Bankey A, Nikolinakos PG, Ali… Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells.